The purpose of this research study is to determine whether a new drug for schizophrenia is
better for the maintenance treatment than a standard drugs currently prescribed. The new
medication is called quetiapine and it will be compared with a standard medication called
haloperidol decanoate. The study will determine if quetiapine causes fewer problems than
haloperidol with side effects such as stiffness and restlessness and whether it costs the VA
more or less to treat patients with quetiapine. In addition, blood samples will be
collected every three months to determine if certain chemicals in the blood can influence
the outcome of the subjects' illness.
1. Schizophrenia or Schizoaffective Disorder diagnosed by DSM-IV
2. Between the ages 18-60.
3. A candidate for maintenance antipsychotic therapy. This means that patients will
have had at least two documented episodes of acute schizophrenic illness or at least
two years of continuing psychotic symptoms.
1. Organic brain disease.
2. Mental Retardation
3. Chronic medical illness which would make antipsychotic medication inappropriate.